Insulet: The Growth Doesn't Stop Here
The market is overstating the impact of GLP-1s and fails to recognize that GLP-1s pose no direct threat to Insulet's customer base. International expansion into Europe (the largest addressable market for T1D) and the shift into MENA focus will drive top-line growth. The T2D market is underpenetrated, representing a wide potential runway, from which PODD is set to win the most based on structural moats.
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.15 per share a year ago.
Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is PODD A Better Bet Than ISRG Stock?
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is it the Right Time to Add Insulet Stock to Your Portfolio?
PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
